vorinostat has been researched along with pyrroles in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Goh, E; Kantharaj, E; New, LS; Pasha, MK; Sangthongpitag, K; Venkatesh, PR; Xin, L; Yeo, P; Zeng, P | 1 |
| Cossío, FP; Otaegui, D; Pedraz, JL; Rodríguez-Gascón, A; Zubia, A | 1 |
| Ballestar, E; Berdasco, M; Boix-Chornet, M; Coll-Mulet, L; Cossío, FP; Esteller, M; Fraga, MF; Gil, J; Martinez, A; Otaegui, D; Ropero, S; Zubia, A | 1 |
| Chandra, J; Keating, MJ; Miller, CP; Palladino, M; Rudra, S; Wierda, WG | 1 |
| Garcia-Manero, G; Hu, Y; Jia, Y; Kadia, T; O'Brien, S; Tambaro, FP; Tong, W; Viallet, J; Wei, Y; Yang, H; Zhang, M | 1 |
| Garcia-Manero, G; Hu, Y; Jia, Y; Kadia, T; O'Brien, S; Tong, W; Viallet, J; Wei, Y; Yang, H; Zhang, M | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Coll-Mulet, L; Cosialls, AM; de Frias, M; de la Banda, E; de Sevilla, AF; Gil, J; González-Gironès, DM; Iglesias-Serret, D; Pérez-Perarnau, A; Pons, G; Rubio-Patiño, C | 1 |
| Drabkin, HA; Gemmill, RM; Lay, A; Lee, L; Lloyd, GK; Longenecker, A; McConkey, DJ; Millward, M; Neuteboom, ST; Palladino, MA; Price, T; Sharma, G; Spear, MA; Spencer, A; Sukumaran, S; Sweeney, C; Townsend, A | 1 |
| Casto, BC; Knobloch, TJ; Lubet, RA; Pereira, MA; Steele, VE; Warner, BM; Weghorst, CM | 1 |
| AnandhaKumar, C; Bando, T; Han, L; Junetha, S; Nagase, H; Pandian, GN; Saha, A; Sato, S; Sugiyama, H; Taniguchi, J; Taylor, RD; Vaijayanthi, T | 1 |
| Kuroda, J | 1 |
| Bando, T; Chandran, A; Li, Y; Sato, S; Sugiyama, H; Syed, J | 1 |
| Kong, HH; Lee, HA; Moon, EK; Quan, FS | 1 |
| Alcitepe, İ; Karatekin, İ; Kaymaz, BT; Salcin, H | 1 |
2 review(s) available for vorinostat and pyrroles
| Article | Year |
|---|---|
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
[Current status of clinical trials of novel agents for multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Approval; Drug Discovery; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lactones; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Pyrroles; Thalidomide; Vorinostat | 2014 |
1 trial(s) available for vorinostat and pyrroles
| Article | Year |
|---|---|
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lactones; Lung Neoplasms; Male; Melanoma; Middle Aged; Pancreatic Neoplasms; Proteasome Inhibitors; Pyrroles; Vorinostat | 2012 |
12 other study(ies) available for vorinostat and pyrroles
| Article | Year |
|---|---|
In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
Topics: Administration, Oral; Animals; Benzimidazoles; Biological Availability; Caco-2 Cells; Cell Membrane Permeability; Cytochrome P-450 Enzyme System; Dogs; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Half-Life; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Metabolic Detoxication, Phase I; Mice; Mice, Inbred BALB C; Microsomes, Liver; Pyrroles; Pyrrolidines; Rats; Rats, Wistar; Vorinostat | 2007 |
Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Female; Glomerular Filtration Rate; Half-Life; Histone Deacetylase Inhibitors; Hydroxamic Acids; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Pyrroles; Tandem Mass Spectrometry; Tissue Distribution; Vorinostat | 2009 |
Identification of (1H)-pyrroles as histone deacetylase inhibitors with antitumoral activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Computer Simulation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Models, Molecular; Pyrroles; Structure-Activity Relationship; Vorinostat; Xenograft Model Antitumor Assays | 2009 |
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
Topics: Acetylation; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Drug Synergism; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Immunoprecipitation; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Oxidative Stress; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Superoxides; Tumor Cells, Cultured; Vorinostat | 2009 |
The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; Indoles; Leukemia; Microscopy, Electron, Transmission; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Vorinostat | 2010 |
The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
Topics: Apoptosis; Autophagy; Benzamides; BH3 Interacting Domain Death Agonist Protein; Cell Line, Tumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; Pyrimidines; Pyrroles; Vorinostat | 2010 |
Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Lymphocytic, Chronic, B-Cell; Pyrroles; RNA, Messenger; Tumor Cells, Cultured; Vorinostat | 2011 |
Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin.
Topics: Animals; Atorvastatin; Colonic Neoplasms; Dimethylhydrazines; Female; Heptanoic Acids; Histone Deacetylase Inhibitors; Hydroxamic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Mice; Nitrosamines; Pyrroles; RNA, Messenger; Urethane; Vorinostat | 2012 |
Distinct DNA-based epigenetic switches trigger transcriptional activation of silent genes in human dermal fibroblasts.
Topics: Animals; Biomarkers; DNA; Epigenesis, Genetic; Fibroblasts; Gene Expression Profiling; Gene Silencing; Genome, Human; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imidazoles; Mice; Nylons; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Untranslated; Skin; Transcriptional Activation; Vorinostat | 2014 |
Genome-Wide Assessment of the Binding Effects of Artificial Transcriptional Activators by High-Throughput Sequencing.
Topics: Binding Sites; DNA; High-Throughput Nucleotide Sequencing; Humans; Hydroxamic Acids; Imidazoles; Molecular Structure; Nylons; Pyrroles; Vorinostat | 2016 |
Histone Deacetylase Inhibitors Enhance the Amoebicidal Effect of Low Concentration of Polyhexamethylene Biguanide by Inducing Apoptosis.
Topics: Acanthamoeba castellanii; Annexin A5; Apoptosis; Benzamides; Biguanides; Cells, Cultured; Disinfectants; Drug Synergism; Epithelium, Corneal; Flow Cytometry; Fluorescein-5-isothiocyanate; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Pyridines; Pyrroles; Vorinostat | 2020 |
HDAC inhibitor Vorinostat and BET inhibitor Plx51107 epigenetic agents' combined treatments exert a therapeutic approach upon acute myeloid leukemia cell model.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Oxazoles; Pyridines; Pyrroles; Vorinostat | 2022 |